SeaStar Medical Announces Details of the Selective Cytopheretic Device Pivotal Study in Critically ill Adults with Acute Kidney Injury
February 15, 2023 16:01 ET
|
SeaStar Medical Holding Corporation
The NEUTRALIZE-AKI study will evaluate safety and efficacy of the SCD’s ability to target and neutralize the highly activated proinflammatory neutrophils and monocytes that drive hyperinflammation ...
SeaStar Medical to Hold Business Update Conference Call on February 15, 2023
February 14, 2023 16:05 ET
|
SeaStar Medical Holding Corporation
DENVER, Feb. 14, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical (Nasdaq: ICU), a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital...
SeaStar Medical Receives FDA Approval to Begin Study with Selective Cytopheretic Device to Reduce Hyperinflammation in Adults with Acute Kidney Injury
February 09, 2023 08:19 ET
|
SeaStar Medical Holding Corporation
Patient enrollment in pivotal clinical study expected to begin in March DENVER, Feb. 09, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical (Nasdaq: ICU), a medical device company developing proprietary...
SeaStar Medical to Present at the Virtual Sequire Biotechnology Conference on February 2, 2023
January 31, 2023 08:00 ET
|
SeaStar Medical Holding Corporation
DENVER, Jan. 31, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical (Nasdaq: ICU), a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital...
SeaStar Medical Submits Investigational Device Exemption (IDE) Application to FDA to Study a Novel Therapy to Reduce Hyperinflammation in Adult Acute Kidney Injury Patients
January 09, 2023 08:25 ET
|
SeaStar Medical Holding Corporation
Building upon demonstrated clinical success, the pivotal study will evaluate the Selective Cytopheretic Device in adults with AKI requiring CKRT DENVER, Jan. 09, 2023 (GLOBE NEWSWIRE) --...
SeaStar Medical’s Lead Product Candidate, the Selective Cytopheretic Device (SCD), Included in Consensus Statement for Pediatric Acute Kidney Injury in First Pediatric Acute Disease Quality Initiative (ADQI) Meeting
November 07, 2022 12:30 ET
|
SeaStar Medical Holding Corporation
– The SCD is currently being evaluated by the FDA for a Humanitarian Device Exemption (HDE) marketing approval for use in children (> 20 kgs) with AKI – The Company expects the FDA to complete...
LMF Acquisition Opportunities and SeaStar Medical Announce Effectiveness of Registration Statement and Special Meeting of Stockholders to be Held October 18, 2022 to Approve Business Combination
September 28, 2022 17:00 ET
|
LMF Acquisition Opportunities Inc.
All stockholders of LMF Acquisition Opportunities as of September 23, 2022 are encouraged to vote their shares as soon as possible before the special meeting Stockholders who need assistance voting...
SeaStar Medical Appoints Dr. Sai Prasad Iyer, Ph.D as VP, Medical Affairs and Clinical Development
September 19, 2022 08:30 ET
|
LMF Acquisition Opportunities Inc.
Denver, Colo. and Tampa, Fla., Sept. 19, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical, a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on...
SeaStar Medical Reports First Successful Treatment of Pediatric Patient with Hemophagocytic Lymphohistiocytosis (HLH) and Multi-Organ Failure with its SCD
August 01, 2022 08:00 ET
|
LMF Acquisition Opportunities Inc.
DENVER, CO and TAMPA, FL, Aug. 01, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical, a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital...
SeaStar Medical Submits Humanitarian Device Exemption Application to FDA for Use of Selective Cytopheretic Device in Children with Acute Kidney Injury
July 20, 2022 08:00 ET
|
LMF Acquisition Opportunities Inc.
DENVER, CO and TAMPA, FL, July 20, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical, a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital...